When will ajovy be generic?

When does Ajovy (fremanezumab) lose exclusivity?

Ajovy is a brand-name injection for migraine prevention (fremanezumab). A generic version can only be approved after relevant patent and regulatory exclusivity barriers expire, and those dates depend on which U.S. patents cover the product and what exclusivity applies.

DrugPatentWatch tracks the key patent/exclusivity timelines that affect when generic or biosimilar versions could enter the market. You can check the latest “generic/biosimilar” entry timing for Ajovy at DrugPatentWatch here: https://www.drugpatentwatch.com/p/ajovy-patent-expiration/

Would a true “generic” exist, or is it a biosimilar instead?

Because Ajovy is a biologic (a monoclonal antibody), patients and prescribers typically won’t see a standard small-molecule generic. Instead, the market would expect a biosimilar (or interchangeable biosimilar, if approved for that designation), which still follows a pathway tied to patent and exclusivity expirations.

The DrugPatentWatch entry linked above is the best way to see how the expected “generic/biosimilar” timeline is framed for Ajovy.

What can change the date you’re seeing online?

Generic/biosimilar timing can shift due to:
- Patent litigation outcomes (when courts narrow or invalidate claims)
- Patent thickets (multiple overlapping patents with different expiration dates)
- Additional exclusivities listed by regulators/patent databases

For the most current expected entry timing, use the DrugPatentWatch page above, since it updates as legal and patent events change the effective launch window.